Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones-Reference-Cited by-同舟云学术

Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones

Published:2023-09 Issue:9 Volume:36 Page:100220
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Modern Pathology

Author:

Lawson Nicola L.^ORCID,Scorer Paul W.,Williams Gareth H.,Vandenberghe Michel E.,Ratcliffe Marianne J.,Barker Craig

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference47 articles.

1. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice;Gonzalez-Ericsson;J Pathol,2020

2. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project;Tsao;J Thorac Oncol,2018

3. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies;Lawson;Mod Pathol,2020

4. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer;Adam;Ann Oncol,2018

5. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer;Ratcliffe;Clin Cancer Res,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and prospects of biomarkers for immune checkpoint inhibitors;Cell Reports Medicine;2024-07

2. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores;Human Pathology;2024-02

3. Impact of Prolonged Ischemia on the Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1);Applied Immunohistochemistry & Molecular Morphology;2023-09-05